RxDoctor Payments Data

Christopher Belleau, MD

Physical Medicine & Rehabilitation · Baton Rouge, LANPI 1568405959

Payments from drug & device makers

What this record shows

This record is dominated by education: $1,872 of the $2,549 with a category attached, or 73.4%. Arthrex accounts for 74.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,939 and has fallen 86.2% since, to $267 in 2025.

$2,549in general payments, 2019–2025

Across 33 payments — averaging $77.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$2K
  • Ipsen Biopharmaceuticals, Inc$284
  • AbbVie$127
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
  • Merz Pharmaceuticals, LLC$31
  • Lundbeck LLC$25
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$67727%
  • Education$1,87273%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,549 in reported general payments places this provider in the 75th percentile of 117 physical medicine & rehabilitation providers in Louisiana.

See all physical medicine & rehabilitation providers in Louisiana

Medicare billing

Part B allowed, 2024
$315,563
Medicare patients
307
Services billed
9,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina22$50,098
Gabapentin93$1,478
Tramadol Hcl40$236
Meloxicam18$203
Tizanidine Hcl24$193
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$187
Baclofen19$174
Celecoxib15$171
Methocarbamol14$92
Allopurinol14$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$127$50,09822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 physical medicine & rehabilitation providers in Louisiana.

Other physical medicine & rehabilitation in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →